Table 1.
Factor Gender | Total N | N (%) with recurrence | Unadjusted risk ratio (95% confidence interval) | Risk ratio adjusted for treatment intensity/weaning (95% confidence interval) | Composite model 1 (Full model)* | Composite model 2 (Reduced model)** |
---|---|---|---|---|---|---|
Female | 31 | 6 (19%) | Reference | Reference | -- | -- |
Male | 38 | 11 (29%) | 1.5 (0.62, 3.6) | 1.4 (0.62, 3.3) | ||
Race | ||||||
White | 60 | 15 (25%) | Reference | Reference | -- | -- |
Other | 9 | 2 (22%) | 0.89 (0.24, 3.3) | 0.81 (0.22, 3.1) | ||
Age at diagnosis | ||||||
<3 | 5 | 1 (20%) | 0.95 (0.72, 1.2) | 0.94 (0.71, 1.2) | -- | -- |
3 to <4 | 9 | 1 (11%) | per year | per year | ||
4 to <5 | 21 | 6 (29%) | ||||
5 to <6 | 18 | 6 (33%) | ||||
6 to <7 | 9 | 0 (0%) | ||||
7 to <8 | 2 | 0 (0%) | ||||
Unknown | 5 | 3 (60%) | ||||
Age at cessation of patching | ||||||
3 to <4 | 4 | 0 (0%) | 0.84 (0.59, 1.2) | 0.83 (0.59, 1.2) | 0.90 (0.64, 1.3) | -- |
4 to <5 | 17 | 6 (35%) | per year | per year | per year | |
5 to <6 | 22 | 6 (27%) | ||||
6 to <7 | 20 | 5 (25%) | ||||
7 to <8 | 6 | 0 (0%) | ||||
Duration of preceding period of patching | ||||||
3 to <6 months | 42 | 12 (29%) | Reference | Reference | Reference | -- |
6 to <9 months | 16 | 1 (6%) | 0.22 (0.03, 1.5) | 0.18 (0.03, 1.2) 0.28 (0.04, 1.8) | ||
≥9 months | 11 | 4 (36%) | 1.3 (0.51, 3.2) | 1.4 (0.62, 3.3) | 0.80 (0.28, 2.2) |
Includes factors with relative risk greater than 2.0 or less than 0.5 (age at cessation of patching, duration of preceding period of treatment, previous amblyopia recurrence, IOD at cessation of patching, and lines improved from diagnosis to enrollment). Amblyopic eye visual acuity at diagnosis and enrollment were not included as they are correlated with IOD at cessation of patching and lines of improvement and the latter are more strongly associated with recurrence. “—“ “indicates that the factor did not meet the criteria for inclusion in the model.
This model eliminates factors that are not statistically significant from the full model, and therefore includes only IOD at cessation of patching, lines of improvement and previous recurrence of amblyopia.